Speech-Language Pathologists in Ashdown, AR Accepting Medicare

5 Speech-Language Pathologists found. Showing 1 - 5

Kelsey Starks, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 974 Lr 17, Ashdown, AR 71822 Phone: 903-277-4451

Mrs. Ashley Renee Sanders, MS CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 460 Nw Front St, Ashdown, AR 71822 Phone: 870-898-4404

Anna Ward Ramage, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 511 N 2nd St, Ashdown, AR 71822 Phone: 870-898-3208

Taylor Elyse Ledford Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 751 Rankin St, Ashdown, AR 71822 Phone: 870-898-3208

Donna K Kneipp-lingle, MA, CCC, SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 460 Nw Front St, Ashdown, AR 71822 Phone: 870-898-4404

News Archive

Embrella Cardiovascular completes first clinical case using Embrella Embolic Deflector

Embrella Cardiovascular, Inc., a privately held company announced that it has completed its first clinical case using the Embrella Embolic Deflector™. The company has developed a novel technology designed to make less invasive cardiovascular procedures safer for patients by decreasing the risk of emboli traveling to the brain.

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

In a phase IIb study in 589 patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid effects in the higher dose arms in both the monotherapy and co-administration treatment groups eight weeks after stopping active therapy with anacetrapib.

Study: Sufficient copies of SMN1 gene extend survival in animals with spinal muscular atrophy

To make up for insufficient amounts of SMN protein, the cause of the inherited neuromuscular disease spinal muscular atrophy (SMA), researchers have successfully delivered a replacement SMN1 gene directly to the spinal cords of animal models of SMA.

LaVision BioTec report on users of light sheet microscopy in the Miami Project to Cure Paralysis

LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on users of their Ultramicroscope Light Sheet Fluorescence Microscope system to aid the research of the Miami Project to Cure Paralysis under the supervision of Professor Vance Lemmon, the Walter G. Ross Distinguished Chair in Developmental Neuroscience & Professor of Neurological Surgery at the University of Miami.

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of LEMTRADA (alemtuzumab) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features.

Read more Medical News

› Verified 5 days ago